TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
Los Alamos National Laboratory (LANL) is offering a technology licensing opportunity for its novel Clathrate Therapeutics Platform. This platform aims to improve the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. This is a Special Notice for potential licensees, not a call for external services. Responses for licensing discussions are encouraged by December 4, 2026.
Opportunity Scope
The Clathrate Therapeutics Platform addresses the challenge of safe, controlled, and localized delivery of therapeutic gases, which have shown promise in oncology, cardiovascular disease, neuroprotection, and regenerative medicine. By temporarily stabilizing gases within a biocompatible structure for gradual, targeted release, the technology minimizes systemic exposure and enhances clinical viability. It also includes a complementary predictive modeling capability to optimize treatment and accelerate development.
Technology Details
The platform uses a proprietary, controlled-release system to localize therapeutic gases, releasing them gradually under physiological conditions. Key advantages include:
- Localized delivery: Minimizes systemic exposure.
- Controlled release: Sustained, tunable dosing.
- Improved safety margin: Separates therapeutic effect from toxicity.
- Platform versatility: Applicable across various medical indications.
- Development optimization: Supported by predictive modeling.
- Partnership-ready: Integrates with drug-device combinations.
Market Applications
This technology is relevant for the:
- Oncology Therapeutics Industry
- Cardiovascular and Vascular Medicine Industry
- Neurology and Neurodegenerative Disease Sector
- Regenerative Medicine and Tissue Engineering Industry
- Medical Device and Drug-Device Combination Companies
- Biotechnology and Specialty Pharma Companies
- Computational Drug Development and Modeling Firms
Opportunity & Timeline
- Type: Technology Licensing Opportunity (Special Notice)
- Development Status: TRL 2, US patent pending
- Response Due: December 4, 2026
- Published: June 4, 2026
- Set-Aside: Not applicable (licensing opportunity)
Additional Notes
This notice is for licensing discussions only and is not a request for external services to develop this technology. Interested parties should contact licensing@lanl.gov for specific discussions.